{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:49:26Z","timestamp":1784555366428,"version":"3.55.0"},"reference-count":42,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica (ANPCyT)","award":["PICT 1866\u20132018"],"award-info":[{"award-number":["PICT 1866\u20132018"]}]},{"name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica (ANPCyT)","award":["PICT 3347-2020"],"award-info":[{"award-number":["PICT 3347-2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Currently, therapy for early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) is based on the combination of trastuzumab and pertuzumab plus chemotherapy in a neoadjuvant regimen. The INMUNOHER study aimed to detect immunological markers in peripheral blood and their association with treatment response. Sixty-two HER2+ BC patients were recruited. Pre-treatment samples were obtained before the start of treatment, while post-treatment samples were obtained after completing therapy and before surgery and were analyzed by flow cytometry. The pathologic complete response (pCR) rate achieved was 82.3%. The expression of the NKp30, PD-1, and TIM-3 receptors was reduced in the Natural Killer (NK)-CD56dim subset of patients who did not achieve pCR. Following therapy, many changes were found in leukocytes, including alterations in T cell lymphocyte proportions. Also, the percentage of NK cells decreased, and several phenotypic changes were observed in this population. After treatment, IFN-\u03b3 production by NK cells against HER2+-cells with or without trastuzumab was significantly reduced. HER2-targeted therapy plus chemotherapy demonstrated high efficacy in most patients, reducing the statistical power for finding immunological markers. However, NK subset phenotypes correlated better with response groups, and numerous changes in the percentage of leukocytes and T and NK cells, as well as changes in the functionality of NK cells, were observed in most patients after treatment, encouraging further research into these immune populations.<\/jats:p>","DOI":"10.3390\/ijms25179268","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T09:26:51Z","timestamp":1724750811000},"page":"9268","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In-Depth Analysis of the Peripheral Immune Profile of HER2+ Breast Cancer Patients on Neoadjuvant Treatment with Chemotherapy Plus Trastuzumab Plus Pertuzumab"],"prefix":"10.3390","volume":"25","author":[{"given":"Ayel\u00e9n Ivana","family":"Pesce Viglietti","sequence":"first","affiliation":[{"name":"Centro de Investigaciones Oncol\u00f3gicas (FUCA), Fundaci\u00f3n C\u00e1ncer, Ciudad Aut\u00f3noma de Buenos Aires C1426AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Bel\u00e9n","family":"Bordignon","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Oncol\u00f3gicas (FUCA), Fundaci\u00f3n C\u00e1ncer, Ciudad Aut\u00f3noma de Buenos Aires C1426AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ostinelli","sequence":"additional","affiliation":[{"name":"Instituto Alexander Fleming, Ciudad Aut\u00f3noma de Buenos Aires C1426AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manglio Miguel","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Clinical Oncology Unit, Hospital Universitario Austral, Derqui-Pilar, Buenos Aires B1629ODT, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8230-8874","authenticated-orcid":false,"given":"Gerardo","family":"Cueto","sequence":"additional","affiliation":[{"name":"Grupo de Bioestad\u00edstica Aplicada, Departamento de Ecolog\u00eda, Gen\u00e9tica y Evoluci\u00f3n, Instituto de Ecolog\u00eda, Gen\u00e9tica y Evoluci\u00f3n de Buenos Aires (IEGEBA-UBA\/CONICET), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Aut\u00f3noma de Buenos Aires C1428AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Bel\u00e9n","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Oncol\u00f3gicas (FUCA), Fundaci\u00f3n C\u00e1ncer, Ciudad Aut\u00f3noma de Buenos Aires C1426AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"Perazzo","sequence":"additional","affiliation":[{"name":"Centro de Educaci\u00f3n M\u00e9dica e Investigaciones Cl\u00ednicas (CEMIC), Ciudad Aut\u00f3noma de Buenos Aires C1431AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mora","family":"Amat","sequence":"additional","affiliation":[{"name":"Instituto Alexander Fleming, Ciudad Aut\u00f3noma de Buenos Aires C1426AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Col\u00f3","sequence":"additional","affiliation":[{"name":"Instituto Alexander Fleming, Ciudad Aut\u00f3noma de Buenos Aires C1426AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0619-7329","authenticated-orcid":false,"given":"Mar\u00eda Victoria","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Instituto Alexander Fleming, Ciudad Aut\u00f3noma de Buenos Aires C1426AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Nervo","sequence":"additional","affiliation":[{"name":"Instituto Alexander Fleming, Ciudad Aut\u00f3noma de Buenos Aires C1426AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Nadal","sequence":"additional","affiliation":[{"name":"Instituto Alexander Fleming, Ciudad Aut\u00f3noma de Buenos Aires C1426AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Crimi","sequence":"additional","affiliation":[{"name":"Centro de Educaci\u00f3n M\u00e9dica e Investigaciones Cl\u00ednicas (CEMIC), Ciudad Aut\u00f3noma de Buenos Aires C1431AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-4638","authenticated-orcid":false,"given":"Ignacio","family":"Mc Lean","sequence":"additional","affiliation":[{"name":"Clinical Oncology Unit, Hospital Universitario Austral, Derqui-Pilar, Buenos Aires B1629ODT, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice Amancay","family":"Spengler","sequence":"additional","affiliation":[{"name":"Clinical Oncology Unit, Hospital Universitario Austral, Derqui-Pilar, Buenos Aires B1629ODT, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Mordoh","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Oncol\u00f3gicas (FUCA), Fundaci\u00f3n C\u00e1ncer, Ciudad Aut\u00f3noma de Buenos Aires C1426AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8387-9011","authenticated-orcid":false,"given":"Pablo","family":"Mand\u00f3","sequence":"additional","affiliation":[{"name":"Centro de Educaci\u00f3n M\u00e9dica e Investigaciones Cl\u00ednicas (CEMIC), Ciudad Aut\u00f3noma de Buenos Aires C1431AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrella Mariel","family":"Levy","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Oncol\u00f3gicas (FUCA), Fundaci\u00f3n C\u00e1ncer, Ciudad Aut\u00f3noma de Buenos Aires C1426AOE, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1158\/1535-7163.MCT-09-1171","article-title":"Activated Phosphoinositide 3-Kinase\/AKT Signaling Confers Resistance to Trastuzumab but Not Lapatinib","volume":"9","author":"Browne","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1038\/modpathol.2010.33","article-title":"Classification and Prognosis of Invasive Breast Cancer: From Morphology to Molecular Taxonomy","volume":"23","author":"Schnitt","year":"2010","journal-title":"Mod. Pathol. an Off. J. United States Can. Acad. Pathol. Inc"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10549-014-3250-x","article-title":"HER2-Family Signalling Mechanisms, Clinical Implications and Targeting in Breast Cancer","volume":"149","author":"Elster","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ackerman, M.E., and Nimmerjahn, F. (2014). Chapter 1\u2014Antibody-Dependent Cellular Cytotoxicity (ADCC). Antibody Fc, Academic Press.","DOI":"10.1016\/B978-0-12-394802-1.00001-7"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/19420862.2015.1022692","article-title":"An Fc Engineering Approach That Modulates Antibody-Dependent Cytokine Release without Altering Cell-Killing Functions","volume":"7","author":"Kinder","year":"2015","journal-title":"MAbs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4049\/jimmunol.1100681","article-title":"Stimulated \u0393\u03b4 T Cells Increase the in Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer","volume":"187","author":"Capietto","year":"2011","journal-title":"J. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1479-5876-6-25","article-title":"Correlation between NK Function and Response to Trastuzumab in Metastatic Breast Cancer Patients","volume":"6","author":"Beano","year":"2008","journal-title":"J. Transl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11991","DOI":"10.1158\/0008-5472.CAN-07-2068","article-title":"Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2","volume":"67","author":"Varchetta","year":"2007","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-04-0225","article-title":"Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2","volume":"10","author":"Gennari","year":"2004","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-Positive Breast Cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.breast.2018.03.006","article-title":"HER2-Positive Breast Cancer: Current and New Therapeutic Strategies","volume":"39","author":"Bellet","year":"2018","journal-title":"Breast"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.015","article-title":"Three-Year Follow-up from a Phase 3 Study of SB3 (a Trastuzumab Biosimilar) versus Reference Trastuzumab in the Neoadjuvant Setting for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer","volume":"120","author":"Pivot","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","article-title":"Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models","volume":"69","author":"Scheuer","year":"2009","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus Trastuzumab in Combination with Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients with HER2-Positive Early Breast Cancer: A Randomized Phase II Cardiac Safety Study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women with Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer (NeoSphere): A Randomised Multicentre, Open-Label, Phase 2 Trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2015.62.1268","article-title":"Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib","volume":"34","author":"Carey","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2016.3824","article-title":"RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial","volume":"3","author":"Fumagalli","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-019-05398-3","article-title":"Pathologic Complete Response and Outcomes by Intrinsic Subtypes in NSABP B-41, a Randomized Neoadjuvant Trial of Chemotherapy with Trastuzumab, Lapatinib, or the Combination","volume":"178","author":"Swain","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/annonc\/mdw262","article-title":"Integrated Evaluation of PAM50 Subtypes and Immune Modulation of PCR in HER2-Positive Breast Cancer Patients Treated with Chemotherapy and HER2-Targeted Agents in the CherLOB Trial","volume":"27","author":"Dieci","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.20.01276","article-title":"Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer","volume":"38","author":"Krop","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","article-title":"Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial","volume":"1","author":"Salgado","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1158\/1078-0432.CCR-17-3431","article-title":"Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer","volume":"24","author":"Tanioka","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e181564","DOI":"10.1001\/jamaoncol.2018.1564","article-title":"Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial","volume":"4","author":"Powles","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/annonc\/mdy530","article-title":"Pathway Level Alterations Rather than Mutations in Single Genes Predict Response to HER2-Targeted Therapies in the Neo-ALTTO Trial","volume":"30","author":"Shi","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1609785","DOI":"10.3389\/pore.2021.1609785","article-title":"Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer\u2014Increasing Rates of Breast Conserving Surgery: A Real-World Experience","volume":"27","author":"Landherr","year":"2021","journal-title":"Pathol. Oncol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.bjc.6602256","article-title":"Evaluation of ER, PgR, HER-2 and Ki-67 as Predictors of Response to Neoadjuvant Anthracycline Chemotherapy for Operable Breast Cancer","volume":"92","author":"Burcombe","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"x219","DOI":"10.1093\/annonc\/mds307","article-title":"Developments in Ki67 and Other Biomarkers for Treatment Decision Making in Breast Cancer","volume":"23","author":"Sheri","year":"2012","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7146172","DOI":"10.1155\/2022\/7146172","article-title":"Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience","volume":"2022","author":"Hall","year":"2022","journal-title":"Breast J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The Biology of Human Natural Killer-Cell Subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Fabbri, A., Nelli, F., Botticelli, A., Giannarelli, D., Marrucci, E., Fiore, C., Virtuoso, A., Scagnoli, S., Pisegna, S., and Alesini, D. (2023). Pathologic Response and Survival after Neoadjuvant Chemotherapy with or without Pertuzumab in Patients with HER2-Positive Breast Cancer: The Neopearl Nationwide Collaborative Study. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1177681"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","article-title":"Neoadjuvant Chemotherapy with Trastuzumab Followed by Adjuvant Trastuzumab versus Neoadjuvant Chemotherapy Alone, in Patients with HER2-Positive Locally Advanced Breast Cancer (the NOAH Trial): A Randomised Controlled Superiority Trial with a Parallel HE","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clbc.2023.03.007","article-title":"Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics","volume":"23","author":"Gradishar","year":"2023","journal-title":"Clin. Breast Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/sj.bjc.6603756","article-title":"Ki-67 as Prognostic Marker in Early Breast Cancer: A Meta-Analysis of Published Studies Involving 12,155 Patients","volume":"96","author":"Cardoso","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Pazina, T., Shemesh, A., Brusilovsky, M., Porgador, A., and Campbell, K.S. (2017). Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions with Diverse Ligands and Alterations in Splice Variant Expression. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00369"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK Cells to Immunotherapy Mediated by PD-1\/PD-L1 Blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","article-title":"Tim-3 Marks Human Natural Killer Cell Maturation and Suppresses Cell-Mediated Cytotoxicity","volume":"119","author":"Ndhlovu","year":"2012","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1158\/2326-6066.CIR-18-0896","article-title":"High Numbers of Circulating CD57(+) NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2(+) Primary Breast Cancer","volume":"7","author":"Muntasell","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12967-015-0567-0","article-title":"Improved Natural Killer Cell Activity and Retained Anti-Tumor CD8(+) T Cell Responses Contribute to the Induction of a Pathological Complete Response in HER2-Positive Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy","volume":"13","author":"Muraro","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1007\/s00262-023-03448-w","article-title":"Phenotypic and Functional Analysis in HER2+\u2009Targeted Therapy of Human NK Cell Subpopulation According to the Expression of Fc\u03b5RI\u03b3 and NKG2C in Breast Cancer Patients","volume":"72","author":"Bordignon","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41416-023-02375-y","article-title":"Alterations in Immune Cell Phenotype and Cytotoxic Capacity in HER2+ Breast Cancer Patients Receiving HER2-Targeted Neo-Adjuvant Therapy","volume":"129","author":"Gaynor","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor Antigen-Specific CD8 T Cells Infiltrating the Tumor Express High Levels of PD-1 and Are Functionally Impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9268\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:43:18Z","timestamp":1760110998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":42,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijms25179268"],"URL":"https:\/\/doi.org\/10.3390\/ijms25179268","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}